As filed with the Securities and Exchange Commission on February 25, 2021 | ||||||||
Registration No. 333- | ||||||||
Jersey (State or other jurisdiction of incorporation or organization) | 98-1057807 (I.R.S. Employer Identification Number) | ||||
Large Accelerated Filer | ☒ | Accelerated Filer | ☐ | |||||||||||||||||
Non-Accelerated Filer | ☐ | Smaller Reporting Company | ☐ | |||||||||||||||||
Emerging Growth Company | ☐ | |||||||||||||||||||
Title Of Securities To Be Registered | Amount To Be Registered (1) | Proposed Maximum Offering Price Per Share (2) | Proposed Maximum Aggregate Offering Price (2) | Amount Of Registration Fee (2) | |||||||||||||
Ordinary shares, no par value | 5,114,843 | $169.77 | $868,346,896.11 | $94,736.65 | |||||||||||||
(1) | This Registration Statement covers (i) 4,091,874 ordinary shares of NovoCure Limited (the “Registrant”) available for issuance pursuant to awards under the NovoCure Limited 2015 Omnibus Incentive Plan (the “2015 Plan”) and (ii) 1,022,969 ordinary shares of the Registrant available for issuance pursuant to the NovoCure Limited Employee Share Purchase Plan (the “ESPP” and, together with the 2015 Plan, the “Plans”). | ||||||||||||||||
In addition, pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement also covers any additional securities of the Registrant that become issuable under the Plans relating to adjustments for changes resulting from a stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration. |
(2) | Completed pursuant to Rule 457(c) and Rule 457(h) of the Securities Act, based on the average of the high and low prices reported for the Registrant’s ordinary shares on the NASDAQ Global Select Market on February 23, 2021. Pursuant to the ESPP, which plan is incorporated by reference herein, the purchase price of the ordinary shares of the Registrant to be issued thereunder will be the lesser of 85% of the fair market value of an ordinary share of the Registrant on the first day of the applicable six-month offering period and 85% of the fair market value of an ordinary share of the Registrant on the last day of the purchase period. |
(a) | The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020, filed on February 25, 2021; and | ||||
(b) | The description of ordinary shares set forth in the Registrant’s registration statement on Form 8-A filed on September 23, 2015 pursuant to Section 12 of the Exchange Act of 1934, as amended (the “ Exchange Act ”), including any amendment or report filed for the purpose of updating such description. |
Exhibit Number | Exhibit Document | ||||
4.1 | |||||
4.2 | |||||
5.1 | |||||
10.1 | |||||
10.2 | |||||
23.1 | Consent of Ogier (included in Exhibit 5.1) * | ||||
23.2 | |||||
24.1 | Power of Attorney (included in signature page)* |
NOVOCURE LIMITED | ||||||||
By: | /s/ Ashley Cordova | |||||||
Ashley Cordova | ||||||||
Chief Financial Officer |
Signatures | Title | Date | |||||||||||||||
By: | /s/ Asaf Danziger | Chief Executive Officer and Director (Principal Executive Officer) | February 25, 2021 | ||||||||||||||
Asaf Danziger | |||||||||||||||||
By: | /s/ Ashley Cordova | Chief Financial Officer (Principal Financial and Accounting Officer) and Authorized Representative in the United States | February 25, 2021 | ||||||||||||||
Ashley Cordova | |||||||||||||||||
By: | /s/ William F. Doyle | Executive Chairman and Director | February 25, 2021 | ||||||||||||||
William F. Doyle | |||||||||||||||||
By: | /s/ Kinyip Gabriel Leung | Director | February 25, 2021 | ||||||||||||||
Kinyip Gabriel Leung | |||||||||||||||||
By: | /s/ Jeryl L. Hilleman | Director | February 25, 2021 | ||||||||||||||
Jeryl L. Hilleman | |||||||||||||||||
By: | /s/ David T. Hung | Director | February 25, 2021 | ||||||||||||||
David T. Hung | |||||||||||||||||
By: | /s/ Martin J. Madden | Director | February 25, 2021 | ||||||||||||||
Martin J. Madden | |||||||||||||||||
By: | /s/ Sherilyn D. McCoy | Director | February 25, 2021 | ||||||||||||||
Sherilyn D. McCoy | |||||||||||||||||
By: | /s/ Timothy J. Scannell | Director | February 25, 2021 | ||||||||||||||
Timothy J. Scannell | |||||||||||||||||
By: | /s/ William A. Vernon | Director | February 25, 2021 | ||||||||||||||
William A. Vernon |
NovoCure Limited Second Floor No. 4 The Forum Grenville Street St Helier Jersey JE2 4UF | D: +44 1534 504298 | |||||||
E: simon.schilder@ogier.com | ||||||||
Ref: SIS/KEG/ZOB/165852.00021 | ||||||||
25 February 2021 |
Ogier (Jersey) LLP 44 Esplanade St Helier Jersey JE4 9WG T +44 1534 514000 F +44 1534 514444 ogier.com | Partners Raulin Amy James Campbell Richard Daggett Simon Dinning Katrina Edge Sally Edwards Damian Evans Simon Felton | James Fox Josephine Howe Jonathan Hughes Niamh Lalor Edward Mackereth Bruce MacNeil Steven Meiklejohn Oliver Passmore | Nathan Powell Sophie Reguengo Daniel Richards Nicholas Williams |
Registered as a limited liability partnership in Jersey. Registered number 99. | BLAW-42297803-1 |
2 | BLAW-42297803-1 |
3 | BLAW-42297803-1 |
4 | BLAW-42297803-1 |
Tel Aviv, Israel | /s/ | KOST FORER GABBAY AND KASIERER | ||||||
February 25, 2021 | A member of Ernst & Young Global |